4.3 Article

A global assessment of cancer genomic alterations in epigenetic mechanisms

期刊

EPIGENETICS & CHROMATIN
卷 7, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1756-8935-7-29

关键词

Epigenetics; Pan-cancer; Chromatin; Mutation; Amplification; RNA-seq

资金

  1. AbbVie [1097737]
  2. Bayer
  3. Boehringer Ingelheim
  4. Canada Foundation for Innovation
  5. Genome Canada through the Ontario Genomics Institute [OGI-055]
  6. GlaxoSmithKline
  7. Janssen
  8. Lilly Canada
  9. Novartis Research Foundation
  10. Ontario Ministry of Economic Development and Innovation
  11. Pfizer
  12. Takeda
  13. Wellcome Trust [092809/Z/10/Z]

向作者/读者索取更多资源

Background: The notion that epigenetic mechanisms may be central to cancer initiation and progression is supported by recent next-generation sequencing efforts revealing that genes involved in chromatin-mediated signaling are recurrently mutated in cancer patients. Results: Here, we analyze mutational and transcriptional profiles from TCGA and the ICGC across a collection 441 chromatin factors and histones. Chromatin factors essential for rapid replication are frequently overexpressed, and those that maintain genome stability frequently mutated. We identify novel mutation hotspots such as K36M in histone H3.1, and uncover a general trend in which transcriptional profiles and somatic mutations in tumor samples favor increased transcriptionally repressive histone methylation, and defective chromatin remodeling. Conclusions: This unbiased approach confirms previously published data, uncovers novel cancer-associated aberrations targeting epigenetic mechanisms, and justifies continued monitoring of chromatin-related alterations as a class, as more cancer types and distinct cancer stages are represented in cancer genomics data repositories.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据